医学
心房颤动
导管消融
窦性心律
决奈达隆
心脏病学
内科学
重症监护医学
胺碘酮
心房颤动的处理
作者
Jordi Heijman,Stefan H. Hohnloser,A. John Camm
出处
期刊:Europace
[Oxford University Press]
日期:2021-04-01
卷期号:23 (Supplement_2): ii14-ii22
被引量:27
标识
DOI:10.1093/europace/euaa426
摘要
Abstract Atrial fibrillation (AF) remains a highly prevalent and troublesome cardiac arrhythmia, associated with substantial morbidity and mortality. Restoration and maintenance of sinus rhythm (rhythm-control therapy) is an important element of AF management in symptomatic patients. Despite significant advances and increasing importance of catheter ablation, antiarrhythmic drugs (AADs) remain a cornerstone of rhythm-control therapy. During the past 50 years, experimental and clinical research has greatly increased our understanding of AADs. As part of the special issue on paradigm shifts in AF, this review summarizes important milestones in AAD research that have shaped their current role in AF management, including (i) awareness of the proarrhythmic potential of AADs; (ii) increasing understanding of the pleiotropic effects of AADs; (iii) the development of dronedarone; and (iv) the search for AF-specific AADs. Finally, we discuss short- and long-term opportunities for better AF management through advances in AAD therapy, including personalization of AAD therapy based on individual AF mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI